Outcomes following first KI discontinuation. PFS (A) and OS (C) of patients after first KI discontinuation (ibrutinib or idelalisib). (B) PFS of patients after first KI discontinuation stratified by first KI choice (ibrutinib vs idelalisib).
Sign In or Create an Account